Clinical Trial

Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions

Study acronym: BioHPV
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Randomized, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-23.
Trial Details
NCT Number NCT07431502
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vulvar Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vaginal Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Penile Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Cervical Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Anal Site
Enrollment 984 participants
Start Date 2026-05
Primary Completion 2030-11 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-27